Unexpected applications of secondary metabolites

Biotechnology Advances

Volumn 29, Issue 2, 2011, Pages 223-229

  Vaishnav, Preeti ^a   Demain, Arnold L ^b  

^a GIDC   (India)

^b DREW UNIVERSITY   (United States)

Author keywords

Antibiotics; Antitumor agents; Cholesterol lowering agents; Immunosuppressants; Natural products; Secondary metabolites

Indexed keywords

AMPHOTERICIN B; ANTI-PRION AGENTS; ANTI-TUMOR ACTIVITIES; ANTI-TUMOR AGENTS; ANTI-TUMORS; ANTIBIOTIC ACTIVITY; ANTIMALARIAL AGENT; ANTITUMOR DRUGS; ARTEMISININ; AZITHROMYCIN; BALLOON ANGIOPLASTY; BETULINIC ACID; BLEOMYCINS; C-REACTIVE PROTEINS; CLARITHROMYCIN; CONTACT DERMATITIS; CYCLOSPORIN; DOXORUBICIN; IMMUNOSUPPRESSANTS; INFLAMMATORY DISEASE; MACROLIDE ANTIBIOTICS; MEDICAL USE; MUSCULAR DYSTROPHY; NATURAL PRODUCTS; PRODIGIOSIN; PULMONARY FUNCTION; RAPAMYCIN; RESTENOSIS; SECONDARY METABOLITES; SKIN DISEASE; SOPHOROLIPIDS; STATINS; TACROLIMUS;

AMIDES; ANIMALS; ANTIBIOTICS; BIOMOLECULES; CHOLESTEROL; DERMATITIS; DERMATOLOGY; METABOLISM; SKIN;

METABOLITES;

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE;

ANTIBIOTICS; DRUG; IMMUNOASSAY; PIGMENT; PROTEIN; SECONDARY METABOLITE; SKIN;

ANIMAL; BLOOD; HUMAN; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; BETA-LACTAMS; BIOLOGICAL PRODUCTS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROLIDES;

ANIMALIA;

EID: 79251595178     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2010.11.006     Document Type: Review

References (86)

1. Anonymous Reliving Iraq. Science 2008, 320:993.
2. Arceci R.J., Stieglitz K., Bierer B.E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992, 80:1528-1536.
3. Balzarini J., Pannecouque C., De Clercq E., Pavlov A.Y., Printsevskaya S.S., Miroshnikova O.V., et al. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics. J Med Chem 2003, 46:2755-2764.
4. Bate C., Salmona M., Diomede L., Williams A. Squalestatin cures prion-infected neurones and protects against prion nerurotoxicity. J Biol Chem 2004, 279:14984-14990.
5. Berriman M., Fairlamb A.H. Detailed characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochem J 1998, 334:437-445.
6. Borman S. The competition for academic positions. Chem Eng News 2002, 80(33):42.
7. Brazil M. Multiple sclerosis. A new use for statins?. Nat Revs/Drug Disc 2002, 1:934.
8. BRNI Press release, FDA gives clinical trial green light on drug to treat Alzheimer's disease. April 22, 2009.
9. Brown A.G., Smale T.C., King T.J., Hassenkamp R., Thompson R.H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin Trans 1976, 1:1165-1170.
10. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003, 100:15113-15118.
11. Chan K.Y., Boucher E.S., Gandhi P.J., Silva M.A. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Amer J Hlth-Syst Pharm 2004, 61:1676-1681.
12. Chen X., Yang L., Zhang N., Turpin J.A., Buckheit R.W., Osterling C., et al. Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Ag Chemother 2003, 47:2810-2816.
13. Chong C.R., Qian D.Z., Pan F., Wei Y., Pili R., Sullivan D.J., et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006, 49:2677-2680.
14. Cisse M., Mucke L. Alzheimer's disease: A prion protein connection. Nature 2009, 457:1090-1091.
15. Cruz M.C., Del Poeta M., Wang P., Wenger R., Zenke G., Quesniaux V.F.J., et al. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Ag Chemother 2000, 44:143-149.
16. Demaimay R., Race R., Chesebro B. Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J Virol 1999, 73:3511-3513.
17. Dobson S., May T., Berriman M., Del Vecchio C., Fairlamb A.H., Chakrabarti D., et al. Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex. Mol Biochem Parasitol 1999, 99:167-181.
18. Donnelly A.C., Mays J.R., Burlison J.A., Nelson J.T., Vielhauer G., Holzbeierlein J., et al. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem 2008, 73:8901-8920.
19. Dufresne C.C., Wilson K.E., Singh S.B., Zink D.L., Bergstrom J.D., Rew D., et al. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod 1993, 56:1923-1929.
20. Durán N., Justo G.Z., Ferreira C.V., Melo P.S., Cordi L., Martins D. Violacein: properties and biological activities. Biotechnol Appl Biochem 2007, 48:127-133.
21. Duran N., Justo G.Z., Melo P.S., De Azevedo M.B.M., Souza Brito A.R.M., Almeida A.B.A., et al. Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Can J Physiol Pharmacol 2003, 81:387-396.
22. Eckstein J.W., Fung J. A new class of cyclosporine analogues for the treatment of asthma. Expert Opin Investig Drugs 2003, 12:647-653.
23. Endo A. Compactin (ML236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J Med Chem 1985, 28:401-405.
24. Filmore D. Progress without profits?. Mod Drug Discovery 2004, 7:17-18.
25. Fogarty M. Saving statins. The Scientist 2003, 17(22):22-23.
26. Forloni G., Iussich S., Awan T., Colombo L., Angeretti N., Girola L., et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002, 99:10849-10854.
27. Fujiwara K., Tsubaki M., Yamazoe Y., Nishiura S., Kawaguchi T., Ogaki M., et al. Fluvastatin Induces apoptosis on human tongue carcinoma cell line HSC-3. J Pharm Soc Jp. (Yakugaku Zasshi) 2008, 128:153-158.
28. Fulda S., Debatin K.-M. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 2005, 7:162-170.
29. Georgiou N.A., van der Bruggen T., Healy D.M.C., van Tienen C., de Bie P., Oudshoorn M., et al. Bleomycin has antiviral properties against drug-resistant HIV strains and sensitises virus to currently used antiviral agents. Int J Antimicrob Ag 2006, 27:63-68.
30. Gold B.G. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs 2000, 9:2331-2342.
31. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis. Involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
32. Golub L.M., Lee H.-M., Ryan M.E., Giannobile W.V., Payne J., Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998, 12:12-26.
33. Goodin S. Novel cytotoxic agents: Epothilones. Amer J Hlth-Syst Pharm 2008, 6(Suppl 3):S10-S15.
34. High K.P. The antimicrobial activities of cyclosporine, FK506 and rapamycin. Transplantation 1994, 57:1689-1700.
35. Hrastar L.M. Statins reduce amyloid-induced inflammation. The Scientist 2005, 19(2):22.
36. Hu G.F. Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci USA 1998, 95:9791-9795.
37. Jerwood S., Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008, 61:362-364.
38. Kadota J., Sakito O., Kohno S., Sawa H., Mukae H., Oda H., et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993, 147:153-159.
39. Kim H., Kim S.J., Park S.N., Oh J.W. Bacterial metabolism of polychlorinated biphenyls. J Microbiol Biotechnol 2004, 14:121-127.
40. Komuro I., Sunazuka T., Akagawa K.S., Yokota Y., Iwamoto A., Omura S. Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPb. Proc Natl Acad Sci USA 2008, 105:12509-12514.
41. Kortmansky J., Schwartz G.K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Investig 2003, 21:924-936.
42. Kuhn D., Coates C., Daniel K., Chen D., Bhuiyan M., Kazi A., et al. Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Frontiers Biosci 2004, 9:2605-2616.
43. Law B.K. Rapamycin: An anticancer immunosuppressant?. Crit Rev Oncol Hematol 2005, 56:47-60.
44. Lederman L. Apoptosis. Biotechniques 2004, 37:520-521.
45. Lee H.-J., Lee H.-J., Magesh V., Nam D., Lee E.-O., Ahn K.S., et al. Shikonin, acetylshikonin, and idobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in Lewis Lung Carcinoma-bearing mice. J. Pharm Soc Jpn (Yakugaku Zasshi) 2008, 128:1681-1688.
46. Lell B., Kremser P.G. Clindamycin as an antimalarial drug: Review of clinical trials. Antimicrob Ag Chemother 2002, 46:2315-2320.
47. Li Y.J., Azuma A., Usuki J., Abe S., Matsuda K., Sunazuka T., et al. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts. Respir Res 2006, 7(1):16.
48. Mangé A., Nishida N., Milhavet O., McMahon H.E.M., Casanova D., Lehmann S. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 2000, 74:3135-3140.
49. Merlini L., Angelin A., Tiepolo T., Braghetta P., Sabatelli P., Zamparelli A., et al. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci USA 2008, 105:5225-5229.
50. Mohi M.G., Boulton C., Gu T.-L., Sternberg D.W., Neuberg D., Griffin J.D., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004, 101:3130-3135.
51. Newman D.J., Shapiro S. Microbial prescreens for anticancer activity. SIM News 2008, 58:132-150.
52. Noda Y., Kaiya T., Kohda K., Kawazoe Y. Enhanced cytotoxicity of some tritepenes toward leukemia L1210 cells cultured in low pH media; possibility of a new mode of cell killing. Chem Pharm Bull 1997, 45:1665-1670.
53. Onyewu C., Blankenship J.R., Del Poeta M., Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors in Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Ag Chemothe. 2003, 47:956-964.
54. Pandey R., Chander R., Sainis K.B. Prodigiosins: A novel family of immunosuppressants with anti-cancer activity. Ind J Biochem Biophys 2007, 44:295-302.
55. Péreg-Tomás R., Montaner B., Llagostera E., Soto-Cerrato V. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 2003, 66:1447-1452.
56. Petersen F. Natural products and innovative therapeutic concepts. SIM Annual Meeting Program and Abstracts, Abstr. S15, p. 60, Chicago, 2005.
57. Pray L. Strange bedfellows in transplant drug therapy. The Scientist 2002, 16(7):36.
58. Rakic B., Brûlotte M., Rouleau Y., Bélanger S. Pezacki JP Bleomycin is a potent small-molecule inhibitor of hepatitis C virus replication. Chem Biochem 2006, 7:1330-1333.
59. Revill W.P., Voda J., Reeves C.R., Chung L., Schirmer A., Ashley G., et al. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exper Ther 2002, 302:1278-1285.
60. Rini B., Kar S., Kirkpatrick P. Temsirolimus. Nat Rev./Drug Disc 2007, 6:599-600.
61. Ruan B., Pong K., Jow F., Bowlby M., Crozier R.A., Liu D., et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA 2008, 105:33-38.
62. Ruangweerayut R., Looareesuwan S., Hutchinson D., Chauemung A., Banmairuroi V., Na-Bangchang K. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute unconmplicated falciparum malaria. Malaria J 2008, 7:225. 10.1186/1475-2875-7-225.
63. Ryan J.F. Minirevolutions. Mod Drug Discovery 2003, 6(11):7.
64. Sánchez C., Braña A.F., Méndez C., Salas J.A. Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis. Chembiochem 2006, 7:1231-1240.
65. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 2003, 4:343-348.
66. Schlitzer M. Antimalarial drugs - What is in use and what is in the pipeline. Arch Pharm Chem Life Sci 2008, 341:149-163.
67. Schultz M.J. Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. J. Antimicrob. Chemother 2004, 54:21-28.
68. Shinkai M., Henke M.O., Rubin B.K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol. Ther. 2008, 117:393-405.
69. Singh N.P., Lai H.C. Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004, 24:2277-2280.
70. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Clin Cancer Res 2007, 13:1775-1782.
71. Stoeltzing O., Meric-Bernstam F., Ellis L.M. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cel 2006, 10:89-91.
72. Stuve O., Youssef S., Dunn S., Slavin A.J., Steinman L., Zamvil S.S. The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell Molec Life Sci 2003, 60:2483-2491.
73. Tanaka H., Matsuzaki K., Nakashima H., Ogino T., Matsumoto A., Ikeda H., et al. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. 1. Taxonomy, fermentation, isolation and physico-chemical properties and biological activities. J Antibiot 1997, 50:58-65.
74. Tewary P., Veena K., Pucadyil T.J., Chattopadhyay A., Madhubala R. The sterol-binding antibiotic nystatin inhibits entry of non-opsonized Leishmania donovani into macrophages. Biochem Biophys Res Commun 2006, 339:661-666.
75. Van Bogaert I.N.A., Saerens K., De Muynck C., Develter D., Soetaert W., Vandamme E.J. Microbial production and application of sophorolipids. Appl Microbiol Biotechnol 2007, 76:23-34.
76. Vishnevetsky D., Patel P., Tijerino H., Gandhi P.J. Sirolimus-eluting coronary stent. Am J Health-Syst Pharm 2004, 61:449-456.
77. Wang Y., Zhao Q., Ma S., Yang F., Gong Y., Ke C. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. IUBMB Life 2007, 59:717-721.
78. Wekerle H. Tackling multiple sclerosis. Nature 2002, 420:39-40.
79. Williamson N.R., Fineran P.C., Leper F.J., Salmond G.P.C. The biosynthesis and regulation of bacterial prodigenes. Nat Rev Microbiol 2006, 4:887-899.
80. Wilson R., Bate C., Boshuizen R., Williams A., Brewer J. Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide. BMC Neurosci 2007, 8:99-111.
81. Wrigley S.K. Pharmacologicallly active agents of microbial action. Microbial Diversity and Bioprospecting 2004, 356-374. ASM Press, Washington, ch. 32. A.T. Bull (Ed.).
82. Wu L.-Z., Zhang H.-T., Han F., Gao Q.-J., Sun G.-Z., Wang Y.-G. Synthesis of one dimensional zinc oxide nanostructure and their applications. Chi J Antibiot 2008, 33:396-402.
83. Xing B., Rao J., Liu R. Novel beta-zlactam antibiotic derivatives: their new applications as gene reporters, antitumor prodrugs and enzyme inhibitors. Mini Rev Med Chem. 2008, 8:455-471.
84. Youssef S., Stüve O., Patarroyo P.J., Ruiz P.J., Radosevich J.L., Hur E.M., et al. The potential therapeutic role of statins in central nervous system autoimmune disorders. Nature 2002, 420:78-84.
85. Zhang J., Liu J., Shen Y., Wei D., Li K. Inhibitive effect of prodigiosin on the proliferation of human malignant pancreatic cancer cells. Med Chem Res 2005, 14:181-197.
86. Zotchev S.B. Chemical diversity of polyene macrolides produced by Streptomyces noursei ATCC 11455 and recombinant strain ERD44 with genetically altered polyketide synthase NysC. Curr Med Chem 2003, 10:211-223.